Prestige Consumer Healthcare Closes LaCorium Deal, Raises $400M in Debt
Prestige Consumer Healthcare finalized its LaCorium Health acquisition, simultaneously pricing $400M in senior notes and scheduling its Q1 FY2027 earnings report.
Prestige Consumer Healthcare (NYSE: PBH) executed three significant corporate moves in a single announcement on July 6, 2026, signaling an aggressive posture heading into its new fiscal year. The Tarrytown, N.Y.-based company closed its previously announced acquisition of LaCorium Health, priced a private offering of $400 million in senior notes, and set August 6, 2026 as the date investors will get their first financial read of how the combined business is performing.
The near-simultaneous closing of the LaCorium acquisition and the debt pricing is a textbook leveraged-buyout sequencing: companies typically price acquisition financing concurrent with deal close to minimize interest rate exposure and execution risk. The $400 million senior notes offering suggests Prestige leaned on the debt markets rather than equity to fund the transaction, a choice that preserves shareholder dilution but increases the company's leverage profile at a time when borrowing costs remain elevated by historical standards.
Read more Ingredion Wins Tate & Lyle With 595p All-Cash Takeover Bid →
LaCorium Health, the acquired entity, expands Prestige's portfolio in the over-the-counter consumer healthcare space, a segment the company has built through a series of bolt-on acquisitions over the years. While the financial terms of the LaCorium deal were not disclosed in the announcement, the scale of the accompanying debt raise offers a rough benchmark for the transaction's magnitude.
Investors will have their first concrete look at how the integration is unfolding when Prestige reports first-quarter fiscal 2027 results on August 6. That report will be closely watched for any early commentary on revenue contribution from LaCorium, integration costs, and whether management updates its full-year guidance to reflect the expanded business. The compressed timeline between deal close and the earnings date means analysts will have little room to revise models before hearing directly from management.
Continue reading at GlobalNewswire.
